Century Therapeutics Q1 net income $76.6M on BMS termination revenue; CNTY-101 dosing started

Century Therapeutics, Inc.

2025-Q1 EPS reported $0.89 revenue$109,164,000

Net income of $76.6M vs $28.1M loss in Q1 2024, driven by $109.2M collaboration revenue from BMS deal termination.
Cash, equivalents, and securities $185.8M as of March 31, 2025, down from $220.1M; estimated runway into Q4 2026.
First patient dosed in Phase 1 CALiPSO-1 trial of CNTY-101 for autoimmune disease; clinical data expected by end of 2025.
CNTY-308 (CD19-targeted CAR-iT) on track to enter IND-enabling studies mid-2025.
R&D expenses increased to $26.6M from $23.4M due to clinical trial costs and preclinical program advancement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.